<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02693613</url>
  </required_header>
  <id_info>
    <org_study_id>1517-CL-0204</org_study_id>
    <nct_id>NCT02693613</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of ASP1517 With Kremezin®</brief_title>
  <official_title>Pharmacokinetic Study of ASP1517 − Evaluation of the Effect of Kremezin® on the Pharmacokinetics of ASP1517 in Non-elderly Healthy Adult Male Subjects, When Administered Concomitantly or in a Time Separated Manner.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the effect of Kremezin® on the pharmacokinetics of
      single dose of ASP1517 in healthy non-elderly adult male subjects when administered
      concomitantly or in a time separated manner.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) parameter of ASP1517: AUCinf</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing</time_frame>
    <description>AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of ASP1517: Cmax</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing</time_frame>
    <description>Cmax: Maximum concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP1517: AUClast</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing</time_frame>
    <description>AUClast: Area under the concentration-time curve from the time of dosing extrapolated to the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP1517: CL/F</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing</time_frame>
    <description>CL/F: Apparent total systemic clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP1517: t1/2</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing</time_frame>
    <description>t1/2: Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP1517: tmax</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing</time_frame>
    <description>tmax: Time of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP1517: tlag</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing</time_frame>
    <description>tlag: Time point prior to the time point corresponding to the first measurable (non-zero) concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP1517: Vz/F</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing</time_frame>
    <description>Vz/F: Apparent volume of distribution during the terminal elimination phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by Adverse events</measure>
    <time_frame>Up to 72 hours after final study drug dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by Vital signs</measure>
    <time_frame>Up to 72 hours after each study drug dosing</time_frame>
    <description>Supine blood pressure, supine pulse rate and axillary body temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by Laboratory tests</measure>
    <time_frame>Up to 72 hours after each study drug dosing</time_frame>
    <description>Hematology, blood biochemistry and urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by Standard 12-lead ECG</measure>
    <time_frame>Up to 72 hours after each study drug dosing</time_frame>
    <description>ECG: Electrocardiogram</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment arm includes 4 periods, single dose of ASP1517 alone, single dose of ASP1517 + Kremezin® without a time lag, single dose of ASP1517 + Kremezin® with a time lag (1 h before ASP1517 administration) and single dose of ASP1517 + Kremezin® with a time lag (1 h after ASP1517 administration)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment arm includes 3 periods, single dose of ASP1517 alone, single dose of ASP1517 + Kremezin® with a time lag (2 h before ASP1517 administration) and single dose of ASP1517 + Kremezin® with a time lag (2 h after ASP1517 administration)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1517</intervention_name>
    <description>Oral</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kremezin®</intervention_name>
    <description>Oral</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight (at screening): ≥50.0 kg and &lt;80.0 kg

          -  Body-mass index (BMI) (at screening): ≥17.6 and &lt;26.4 kg/m2

          -  Subject must agree to use contraception consisting of two established forms (1 of
             which must be a barrier method) starting at the time of informed consent and
             continuing throughout the treatment period and for 84days after ASP1517 administration
             in the last period:

          -  Subject must agree not to donate sperm starting at the time of informed consent and
             continuing throughout 84 days after the last administration of ASP1517 in the last
             period.

        Exclusion Criteria:

          -  Received or is scheduled to receive any investigational drugs in other clinical trials
             or post-marketing studies within 120 days before screening or during the period from
             screening to the hospital admission day of the Period 1 (Day −1).

          -  Received or is scheduled to receive medications (including over-the-counter [OTC]
             drugs) within 7 days before the hospital admission day of the Period 1 (Day −1).

          -  Received or is scheduled to receive supplements within 7 days before the hospital
             admission day of the Period 1 (Day −1).

          -  Deviates from any of the normal range of blood pressure, pulse rate, body temperature
             and standard 12-lead electrocardiogram (ECG) specified at screening or the hospital
             admission day of the Period 1 (Day −1).

          -  Meets any of the following criteria for laboratory tests at screening or the hospital
             admission day of the Period 1 (Day −1). Normal ranges of each test specified at the
             study site or the test/assay organization will be used as the normal ranges in this
             study.

          -  Concurrent or previous drug allergies.

          -  Development of (an) upper gastrointestinal symptoms within seven days before the
             hospital admission day of the Period 1 (Day −1).

          -  Concurrent or previous hepatic disease, heart disease, respiratory disease,
             gastrointestinal disease, gastrointestinal obstruction,oesophageal varices, renal
             disease, endocrine disease, cerebrovascular disorder, malignant tumor, retinal
             neovascular lesions and macular edema.

          -  Concurrent chronic constipation or diarrhoea.

          -  A history of digestive tract excision.

          -  Previous use of hypoxia inducible factor-prolyl hydroxylase inhibitors (HIF-PHI) such
             as ASP1517 (FG-4592), YM311 (FG-2216) or erythropoietin products.

          -  Excessive alcohol or smoking habit.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site JP00001</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2016</study_first_posted>
  <last_update_submitted>June 17, 2016</last_update_submitted>
  <last_update_submitted_qc>June 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-drug interaction</keyword>
  <keyword>Kremezin</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>ASP1517</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

